此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Preventing Lymphedema in Patients Undergoing Surgical Treatment for Head and Neck Cancer Through Vein Reconstruction

2026年8月18日 更新者:Shaum Sridharan、University of Pittsburgh

Lymphedema Prevention With Facial Vein Preservation or Reconstruction During Neck Dissection for Operable Head & Neck Cancer

* The goal of this clinical trial is to learn if facial vein reconstruction after neck dissection works to reduce rates of lymphedema in adults getting surgical treatment for head and neck cancer.

This is a trial which aims to improve the rate of lymphedema for patients undergoing treatment for head and neck cancer. Our aim is to re-establish venous flow across the facial vein to improve lymphatic drainage after neck dissection.

  • The investigators will also evaluate lymphatic flow before and after facial vein reconstruction to determine if there is evidence of lymphedema.
  • The main questions this study aims to answer are:

    1. Does facial vein reconstruction after neck dissection improved lymphatic flow in head and neck cancer patients?
    2. Determine if there are changes in lymphatic flow before and after facial vein reconstruction?

After the study is completed, the investigators will compare rates of lymphedema and quality of life in patients with facial vein preservation/reconstruction as compared to previous patients treated for head and neck cancer without facial vein reconstruction.

Participants will undergo the following:

  1. Oncologic and reconstructive surgery as normal. No changes in cancer treatment will occur due to the study.
  2. When necessary, participants will undergo facial vein reconstruction immediately after neck dissection
  3. Visit the clinic once every 3 months for routine checkups and tests. This is typical for most patients treated for head and neck cancer including those not enrolled in the trial.
  4. Fill out short questionnaires to help understand quality of life after head and neck cancer treatment
  5. Undergo lymphography in the OR and at the 1-year mark in the office. This is a simple test performed without radiation exposure. It requires 3 very small skin injections to perform the test.

研究概览

地位

尚未招聘

条件

研究类型

介入性

注册 (估计的)

37

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Pennsylvania
      • Pittsburgh、Pennsylvania、美国、15213
        • UPMC Presbyterian Hospital and UPMC Shadyside Hospital
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

  • 成人
  • 年长者

接受健康志愿者

不

描述

Inclusion Criteria:

  • Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
  • Ability to comply with the study protocol, including follow up visits and additional requirements for data collection
  • Ability to provide informed consent
  • Patients requiring unilateral or bilateral neck dissection. Patients must undergo at least three level neck dissection which must include level 1B
  • Patients will undergo radiotherapy +/-chemotherapy after surgery for HNC. Patients will be required to have adjuvant therapy after surgery to have similar risk of development of lymphedema.
  • No history of allergy to indocyanine green.

Exclusion Criteria:

  • Shellfish Allergy
  • Contraindication to surgery under general anesthesia
  • Prior head and neck surgery, radiation, or chemotherapy for HNC
  • Patients requiring sacrifice of the internal jugular vein or resection of neck skin for oncologic care
  • Anticipated partial or total laryngectomy
  • Pregnancy or lactation

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
实验性的:Facial Vein Reconstruction Group
When necessary, participants will get facial vein reconstruction immediately after neck dissection. Participants will also undergo lymphography before and after vein reconstruction. If the facial vein is intact, no intervention is needed, but the patient may still participate in the study.
Immediately after neck dissection, the facial vein will be assessed. If the vein has been ligated for the neck dissection, then the vein will be repaired. This may require vein graft and the use of a venous coupler. If the vein is intact after neck dissection, we can proceed without surgical intervention.

研究衡量的是什么?

主要结果指标

结果测量
措施说明
大体时间
Lymphedema Staging
大体时间:before surgery and every three months after surgery up to 1 year

The primary endpoint is the presence or absence of head and neck lymphedema (HNL) at follow-up, assessed using the MD Anderson Cancer Center Head and Neck Lymphedema (MDACC HNL) Scale.

This scale is measured from 0 to 2. As the numbers increase, the severity of lymphedema increases. A score of 0 means there was no lymphedema present

before surgery and every three months after surgery up to 1 year

次要结果测量

结果测量
措施说明
大体时间
internal lymphedema
大体时间:before surgery and every 3 months after surgery up to 1 year

We will utilize the Patterson Internal lymphedema scale to assess lymphedema during routine flexible laryngoscopy in the clinic. Patient will be undergoing flexible laryngoscopy as part of routine surveillance.

Several sites within the larynx and hypopharynx are graded as to the severity of edema(swelling). Each site is rated as none, mild, moderate, or severe edema.

before surgery and every 3 months after surgery up to 1 year
Head and Neck Lymphedema and Fibrosis Symptom Inventory
大体时间:These will be performed before surgery and every 3 months after surgery up to 1 year

The Head and Neck Lymphedema and Fibrosis Symptom Inventory (HNLEF) is the only validated symptom scale specific for HNL. HNLEF represents a 33 item survey around 7 domains of survivorship including soft tissue and neurologic toxicity, social functioning, oral dysfunction, body image, taste and swallowing, mucosal irritation, and communication. HNLEF has been shown to capture HNL-related symptom burden and functional impairments. Quality of life in regards to head and neck lymphedema are deemed worse with higher scores.

This tool contains 33 items (symptoms), which are answered in a "yes" or "no" format. If patients answer "yes" to any given item, they are then asked to rate the intensity of the respective symptom on a five-point scales. Each item then receives a score ranging from "0" (Does not experience the symptom) to "5" (Experiences the symptom with severe intensity). Scores can be examined with individual symptoms or based on average score for each subscale.

These will be performed before surgery and every 3 months after surgery up to 1 year
Indocyanine Green Near-infrared imaging
大体时间:intraoperatively and at 1 year following surgery

We will identify quality of head and neck lymphatic flow including disruption of lymphatic pathways and areas of pooling of indocyanine green.

Several observations will be recorded based on imaging. These will be deemed as present or absent without scale.

  • Presence of pooling demonstrating disrupted lymphatic pathways
  • Lymphatic escape pathways
  • Lymphatic flow across facial vein
  • Presence of lymphatic disruption not addressed by facial vein preservation/reconstruction
intraoperatively and at 1 year following surgery
The University of Washington Quality of Life
大体时间:Before surgery and every 3 months up to 1 year after treatment.
The University of Washington Quality of Life (UW-QOL Version 4) is a validated and reliable measure of physical and social-emotional QOL widely used in head and neck cancer. Twelve items assessing appearance, swallowing, chewing, speech, taste, saliva, pain, activity, recreation, shoulder function, mood, and anxiety are scored on a scale from 0 (worst possible response) to 100 (best possible response). Physical and social-emotional subscale scores range from 0 to 100, with higher scores indicating better QOL. A minimal clinically important difference (MCID) on the UW-QOL v4 subscales is generally considered to be approximately 5 points, representing a change that patients are likely to perceive as meaningful. A moderate clinically important change has been estimated at approximately 10 points, reflecting a more substantial improvement in patient-reported outcomes.
Before surgery and every 3 months up to 1 year after treatment.
The Functional Oral Intake Scale
大体时间:Before surgery and every 3 months up to 1 year after treatment
The Functional Oral Intake Scale (FOIS) can be utilized to measure oral intake ability before and after treatment. FOIS has been used across specialties and utilized a grading symptoms from 1-5. Level 1 indicates nothing taken orally; Level 2 indicates tube reliance with few attempts to take food or drinks orally; Level 3 indicates tube dependence with regular oral intake of food or liquids; Level 4 indicates a total oral diet but requires special preparations, compensations, or not expanded from whole-bottle feeding; and Level 5 indicates a total oral diet without special preparation. A higher score represents more swallowing disability
Before surgery and every 3 months up to 1 year after treatment

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Shaum Sridharan, M.D.、Shaum Sridharan, Associate Professor, University of Pittsburgh Medical Center

出版物和有用的链接

负责输入研究信息的人员自愿提供这些出版物。这些可能与研究有关。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (估计的)

2026年9月1日

初级完成 (估计的)

2028年7月1日

研究完成 (估计的)

2028年12月1日

研究注册日期

首次提交

2026年7月3日

首先提交符合 QC 标准的

2026年7月3日

首次发布 (实际的)

2026年7月10日

研究记录更新

最后更新发布 (实际的)

2026年8月19日

上次提交的符合 QC 标准的更新

2026年8月18日

最后验证

2026年8月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

不

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅